JPWO2022035828A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022035828A5 JPWO2022035828A5 JP2023509723A JP2023509723A JPWO2022035828A5 JP WO2022035828 A5 JPWO2022035828 A5 JP WO2022035828A5 JP 2023509723 A JP2023509723 A JP 2023509723A JP 2023509723 A JP2023509723 A JP 2023509723A JP WO2022035828 A5 JPWO2022035828 A5 JP WO2022035828A5
- Authority
- JP
- Japan
- Prior art keywords
- mtx
- pegylated uricase
- patient
- administration
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063063826P | 2020-08-10 | 2020-08-10 | |
| US63/063,826 | 2020-08-10 | ||
| US202163148982P | 2021-02-12 | 2021-02-12 | |
| US63/148,982 | 2021-02-12 | ||
| PCT/US2021/045350 WO2022035828A1 (en) | 2020-08-10 | 2021-08-10 | Methods of treating gout |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023537403A JP2023537403A (ja) | 2023-08-31 |
| JPWO2022035828A5 true JPWO2022035828A5 (https=) | 2024-08-20 |
| JP2023537403A5 JP2023537403A5 (https=) | 2024-08-20 |
Family
ID=80247297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509723A Pending JP2023537403A (ja) | 2020-08-10 | 2021-08-10 | 痛風を治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230301999A1 (https=) |
| EP (2) | EP4192581A4 (https=) |
| JP (1) | JP2023537403A (https=) |
| KR (1) | KR20230086660A (https=) |
| CN (1) | CN116261463A (https=) |
| AU (1) | AU2021324665A1 (https=) |
| BR (1) | BR112023002458A2 (https=) |
| CA (1) | CA3189100A1 (https=) |
| IL (1) | IL300536A (https=) |
| MX (1) | MX2023001740A (https=) |
| WO (1) | WO2022035828A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE052976T2 (hu) | 2005-04-11 | 2021-06-28 | Horizon Pharma Rheumatology Llc | Urát-oxidáz variáns formái és azok alkalmazása |
| HUP1200205A3 (en) | 2009-06-25 | 2012-09-28 | Savient Pharmaceuticals | Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy |
| US20200237881A1 (en) | 2019-01-30 | 2020-07-30 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| CN110234340A (zh) | 2016-11-11 | 2019-09-13 | 好利恩风湿病制药有限责任公司 | 泼尼松和尿酸酶分子的组合疗法及其用途 |
| US12121566B2 (en) | 2019-01-30 | 2024-10-22 | Horizon Therapeutics Usa, Inc. | Methods for treating gout |
| MX2023001740A (es) * | 2020-08-10 | 2023-04-05 | Horizon Therapeutics Usa Inc | Metodos de tratamiento de la gota. |
| CN120152732A (zh) * | 2022-10-24 | 2025-06-13 | 西湖生物医药科技(上海)有限公司 | 诱导特异性免疫耐受的组合 |
| US12201413B2 (en) | 2023-03-01 | 2025-01-21 | Washington University | Free breathing dynamic contrast enhanced (DCE) liver MR imaging |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| ES2245114T3 (es) | 1998-08-06 | 2005-12-16 | Mountain View Pharmaceuticals, Inc. | Conjugados de peg-oxidasa de urato y su uso. |
| JP2002524053A (ja) * | 1998-08-06 | 2002-08-06 | デューク・ユニバーシティー | 尿酸オキシダーゼ |
| HUE052976T2 (hu) | 2005-04-11 | 2021-06-28 | Horizon Pharma Rheumatology Llc | Urát-oxidáz variáns formái és azok alkalmazása |
| WO2006110761A2 (en) | 2005-04-11 | 2006-10-19 | Savient Pharmaceuticals, Inc. | A variant form of urate oxidase and use thereof |
| CN101622270B (zh) | 2006-04-12 | 2014-01-01 | 萨文特医药公司 | 用阳离子表面活性剂纯化蛋白质的方法 |
| HUP1200205A3 (en) | 2009-06-25 | 2012-09-28 | Savient Pharmaceuticals | Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy |
| ES2986077T3 (es) * | 2016-03-11 | 2024-11-08 | Cartesian Therapeutics Inc | Formulaciones y dosis de uricasa pegilada |
| CN110234340A (zh) | 2016-11-11 | 2019-09-13 | 好利恩风湿病制药有限责任公司 | 泼尼松和尿酸酶分子的组合疗法及其用途 |
| US20200237881A1 (en) * | 2019-01-30 | 2020-07-30 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| WO2018169811A1 (en) * | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| WO2020160324A1 (en) * | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| MX2023001740A (es) * | 2020-08-10 | 2023-04-05 | Horizon Therapeutics Usa Inc | Metodos de tratamiento de la gota. |
-
2021
- 2021-08-10 MX MX2023001740A patent/MX2023001740A/es unknown
- 2021-08-10 US US18/020,761 patent/US20230301999A1/en active Pending
- 2021-08-10 WO PCT/US2021/045350 patent/WO2022035828A1/en not_active Ceased
- 2021-08-10 EP EP21856554.7A patent/EP4192581A4/en not_active Withdrawn
- 2021-08-10 BR BR112023002458A patent/BR112023002458A2/pt unknown
- 2021-08-10 KR KR1020237008344A patent/KR20230086660A/ko active Pending
- 2021-08-10 CN CN202180053221.3A patent/CN116261463A/zh active Pending
- 2021-08-10 EP EP25163173.5A patent/EP4588513A3/en active Pending
- 2021-08-10 IL IL300536A patent/IL300536A/en unknown
- 2021-08-10 JP JP2023509723A patent/JP2023537403A/ja active Pending
- 2021-08-10 AU AU2021324665A patent/AU2021324665A1/en active Pending
- 2021-08-10 CA CA3189100A patent/CA3189100A1/en active Pending
-
2022
- 2022-02-09 US US17/668,015 patent/US20220323445A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2693992C (en) | Methods of improving the pharmacokinetics of doxepin | |
| KR20200010320A (ko) | 치료 방법 | |
| JP2002510612A (ja) | 健康および安寧の向上のために使用される物質の効力の最大化 | |
| JP2015526458A5 (https=) | ||
| TW200412934A (en) | Pharmaceutical formulations of modafinil | |
| JPH06192105A (ja) | ホモシステインのレベルを下げるための医薬製剤 | |
| JP2017128610A (ja) | 併用ａｌｓ療法 | |
| JPWO2022035828A5 (https=) | ||
| Weiner et al. | Efficacy and safety of sustained-release diltiazem in stable angina pectoris | |
| US6521254B2 (en) | Single-dose antihistamine/decongestant formulations for treating rhinitis | |
| CN101466385B (zh) | 类风湿病的延迟释放糖皮质激素治疗 | |
| HK1052655A1 (zh) | 用於治療對抗高血壓藥的抗藥性和相關病症的方法和製劑 | |
| JP2004525143A5 (https=) | ||
| Canny et al. | Does ketotifen have a steroid-sparing effect in childhood asthma? | |
| US20070105817A1 (en) | Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension | |
| JP7738832B2 (ja) | 低亜鉛血症治療剤 | |
| RU2023105050A (ru) | Способы лечения подагры | |
| WO2019004465A1 (ja) | ペマフィブラートを含有する医薬 | |
| CN116157119A (zh) | 一种ARNi与钙离子拮抗剂的药物组合物与应用 | |
| JP6420923B1 (ja) | 医薬 | |
| CN117425477A (zh) | 包含1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的药物组合物 | |
| CN114929229A (zh) | 用米立可兰治疗抗精神病药导致的体重增加的方法 | |
| JP2012031141A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| CN102274160B (zh) | 用于治疗对抗高血压药的抗药性和相关病症的方法和制剂 | |
| JP3885135B2 (ja) | Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤 |